AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.28 ($514.64–$521.48, $4.91M total) across 8 trades on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Aug 27, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which can influence short‑term price action.

02

Market read

First‑report insider sell of a mid‑cap biotech; modest trading relevance.

03

What to watch

Sale executed via pre‑arranged 10b5‑1 plan, reducing signaling strength.

Relevance 5/10Novelty 8/10Timing: post‑market 2026‑08‑26

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $4.9M of UTHR shares via a 10b5‑1 plan on 2026‑08‑26.

Expected impact

Potential modest dip as market digests insider sell.

Evidence & confidence

Sale represents ~1.5% of holdings; size and insider role suggest a bearish signal.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

U.S. market only; no broader regional effect.

Global

Limited to investors tracking United Therapeutics.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • person
    Martine Rothblatt

    Chairperson & CEO of United Therapeutics

  • company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for pulmonary arterial hypertension.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min